Please assess the completion status of the following clinical trial:

Trial Title: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic disease~* At least one mesurable lesion according to RECIST V1.1 criteria~* No prior chemotherapy (excepted if there is at least on lestion out of the irradition area)~* Age \> 18 years. A favorable adviced by an onco geriatrician would be mandatory for inclusion of patients older than 75 older~* Performance statut (WHO) 0-1~* Polynyclear ≥ 1500/mm3~* Bilirubine ≤ 1,5 fois la LSN, creatinin \< 120μmol / L~* Signed informed consent form~Exclusion Criteria:~* Another type of pancreas tumor, as endocrine tumor ou with acinous cells~* Ampulloma~* Cerebral or meningeal metastasis~* Gilbert disease~* Neuropathie \> or = grade 1~* Study treatments contraindication~* Uncontrolled diarrhoea or inflamatory disease of colon or rectum, or bowel obstruction or bowel sub-obstruction no resolved with specific treatment~* Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease prevent patient to receive study Cancer within the 5 years before inclusion, except for int situ cancer of the neck of the uterus or basal cell skin cancer~* Significant previous cardiac and respiratory disease~* Patient included in an other therapeutic study with experimental treatment~* Pregnancy or breast feeding~* Patient depreved of freedom or under gardianship~* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFIRINOX (Type: ACTIVE_COMPARATOR): Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
- FOLFIRINOX + LV5FU2 in maintenance (Type: EXPERIMENTAL): Folfirinox during 4 months followed by LV5FU2 maintenance until progression:~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours.
- FIRGEM (Type: EXPERIMENTAL): Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete